Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting.
INTRODUCTION
In advanced-stage (stage IIIB or IV) non-small-cell lung cancer (NSCLC), doublet combinations of platinum compounds (cisplatin or carboplatin) with gemcitabine, vinorelbine, or taxanes (paclitaxel or docetaxel) are reference regimens. 1 When compared head-to-head in phase III studies, these doublets have shown comparable efficacy, with differences in toxicity profiles. [2] [3] [4] [5] Cisplatin plus gemcitabine, in a 3-week schedule, is an effective widely used regimen for first-line treatment of NSCLC. 3, 6 Pemetrexed is a potent inhibitor of thymidylate synthase 7, 8 and other folate-dependent enzymes, including dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. 9 Pemetrexed is currently approved in combination with cisplatin for first-line treatment of malignant pleural mesothelioma 10 and as a single agent for second-line treatment of advanced NSCLC.
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In phase II studies in chemotherapy-naive patients with NSCLC, pemetrexed in combination with cisplatin or carboplatin has yielded efficacy results comparable with other platinum doublets.
In addition, pemetrexed has an excellent safety profile and a convenient administration schedule.
More recently, the addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor, to paclitaxel and carboplatin led to a significant survival benefit; however, this efficacy benefit was seen with an increased risk of treatment-related deaths. 16 In a confirmatory study, the addition of bevacizumab to cisplatin/ gemcitabine led to a statistically significant improvement in progression-free survival (PFS). 17 In both of these studies, safety issues that emerged from a previous phase II randomized study were considered, 18 and consequently, restrictive eligibility criteria were adopted. The primary objective of this phase III noninferiority study was to compare the overall survival of cisplatin/pemetrexed with cisplatin/gemcitabine in chemotherapy-naive patients with advanced NSCLC.
PATIENTS AND METHODS

Patients
Chemotherapy-naive patients with histologically or cytologically confirmed NSCLC, classified as stage IIIB not amenable to curative treatment or stage IV, with at least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumors, 19 with an Eastern Cooperative Oncology Group performance status of 0 or 1, 20 and at least 18 years of age were eligible. Patients had adequate bone marrow reserve and organ function including calculated creatinine clearance Ն 45 mL/min based on the standard Cockcroft and Gault formula. 21 Prior radiation therapy was permitted if it was completed at least 4 weeks before study treatment and patients had fully recovered from its acute effects.
Exclusion criteria included peripheral neuropathy Ն National Cancer Institute Common Toxicity Criteria 22 grade 1, progressive brain metastases, or uncontrolled third-space fluid retention before study entry. Patients were also excluded if they were unable to interrupt aspirin and other nonsteroidal anti-inflammatory drugs or if they were unable or unwilling to take folic acid, vitamin B 12 , or corticosteroids.
The protocol was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines 23 and was approved by each participating institutional ethics review board. All patients signed written informed consent before treatment.
Study Design and Treatment Plan
Eligible patients were randomly assigned to receive either cisplatin 75 mg/m 2 on day 1 plus gemcitabine 1,250 mg/m 2 on days 1 and 8 or cisplatin 75 mg/m 2 plus pemetrexed 500 mg/m 2 on day 1. Pocock and Simon 24 random assignment was used according to disease stage (IIIB v IV), performance status (0 v 1), history of brain metastases (yes v no), sex (male v female), pathologic diagnosis (histologic v cytologic), and investigative center.
Chemotherapy was repeated every 3 weeks for a maximum of six cycles (unless there was earlier evidence of disease progression or intolerance of the study treatment). Patients on both arms received dexamethasone prophylaxis of 4 mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. All patients received oral folic acid (350 to 1,000 g) daily and a vitamin B 12 injection (1,000 g) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment.
Patients requiring a day-1 dose reduction of pemetrexed, gemcitabine, or cisplatin received the reduced dose for the remainder of the study. Patients who had two dose reductions on day 1 and who experienced toxicity requiring a third dose reduction were discontinued from study therapy. Cycle delays of up to 42 days were permitted for recovery from adverse events. Within-cycle (day 8) dose reductions and omissions were allowed for gemcitabine. Concomitant supportive therapies, such as erythropoietic agents or granulocyte colony-stimulating factors, were allowed according to the American Society of Clinical Oncology guidelines. 25 The study protocol requested, in a nonmandatory way, the collection of tumor samples for assessment of candidate biomarkers. Details about these data will be reported separately.
Baseline and Treatment Assessments
Before entering the study, patients underwent a medical history, physical examination, and tumor measurements of palpable lesions as well as lesions assessed by imaging techniques (positron emission tomography and ultrasound scans were not permitted). The baseline assessment method was repeated every other cycle and then every 6 weeks after treatment discontinuation until disease progression. Disease status was assessed according to Response Evaluation Criteria in Solid Tumors. 19 Randomly assigned patients who met the eligibility criteria and who had baseline imaging and at least one scan after starting chemotherapy were considered assessable for tumor response and duration of response. All patients who received at least one dose of pemetrexed, gemcitabine, or cisplatin were considered assessable for safety. Patients were assessed for toxicity according to the National Cancer Institute Common Toxicity Criteria, version 2.0. 22 Efficacy analyses, including the primary end point of overall survival, incorporated all randomly assigned patients on an intent-to-treat basis. Secondary end points included PFS, time to progressive disease, time to treatment failure, objective tumor response rate, duration of response, and toxicity.
Statistical Analyses
Using a noninferiority design, this study compared overall survival between the two treatment arms using a fixed margin method. Assuming a hazard ratio (HR) of 1.0 and including all randomly assigned patients, when at least 1,190 deaths occurred, the analysis provided 80% power to reject the null hypothesis (H 0 ). The H 0 assumed that cisplatin/gemcitabine would provide a Ն 15% reduction in the risk of death over cisplatin/pemetrexed, corresponding to a fixed margin of 1.176. Using the Cox proportional hazards model 26 (with preplanned adjustments for sex, diagnosis [histologic v cytologic], disease stage, and performance status) and two-tailed 95% CIs for the HR, rejection of the H 0 occurred when the upper bound of the HR's 95% CI was less than 1.176.
Cox proportional hazard models were also used to compare the other time-to-event end points between the treatment arms and to test for treatment-by-histology interaction; the Kaplan-Meier 27 method was used to estimate the medians for time-to-event parameters. Tests were conducted as follows: noninferiority tests at one-sided ␣ ϭ .025 level; superiority tests at two-sided ␣ ϭ .05 level; and two-sided CIs at 95%. Tumor response was compared using the normal approximation test for superiority. The incidences of toxicities, hospitalizations, and supportive care were analyzed using Fisher's exact test and analysis of variance (as appropriate). Prespecified analyses of overall survival by random assignment factors included age group, race, smoking status, and histology. All HRs are reported as adjusted, unless otherwise specified. P values were not adjusted for multiple comparisons.
RESULTS
Patient Characteristics
From July 2004 to December 2005, a total of 1,725 patients were randomly assigned (863 patients to cisplatin/gemcitabine and 862 patients to cisplatin/pemetrexed). The baseline patient and diseaserelated characteristics were well balanced between the two treatment arms ( Table 1 ).
All 1,725 patients were evaluated for efficacy, whereas 1,669 patients (cisplatin/gemcitabine, n ϭ 830, 96.2%; cisplatin/pemetrexed, n ϭ 839, 97.3%) were eligible for the safety analyses (Fig 1) . As of Table 2 indicates that a median number of five cycles was administered on both arms. Dose adjustments (delays, reductions, and omissions) were less frequent in patients treated with cisplatin/pemetrexed compared with cisplatin/gemcitabine, even when considering the more frequent gemcitabine dosing (days 1 and 8 for gemcitabine v only day 1 for pemetrexed). On day 1, cisplatin/pemetrexed dose reductions were much less frequent (cisplatin, n ϭ 64; pemetrexed, n ϭ 54 v cisplatin, n ϭ 154; gemcitabine, n ϭ 362) and were mainly caused by neutropenia, whereas cisplatin/gemcitabine dose reductions were most commonly attributable to neutropenia, thrombocytopenia, febrile neutropenia, and leukopenia. On day 8, 339 gemcitabine doses (9.3%) were omitted. Delivered dose-intensities were higher for cisplatin/pemetrexed (95.0% and 94.8%, respectively) than for cisplatin/gemcitabine (93.5% and 85.8%, respectively).
Efficacy
Overall survival for patients randomly assigned to cisplatin/pemetrexed was noninferior to the overall survival of patients assigned to cisplatin/gemcitabine (median overall survival, 10.3 v 10.3 months; HR ϭ 0.94, 95% CI, 0.84 to 1.05), with the CIs for the HR well below the 1.176 noninferiority margin. Figure 2 shows the Kaplan-Meier curve for overall survival. Survival rates at 12 and 24 months were 43.5% and 18.9% for cisplatin/pemetrexed, respectively, and 41.9% and 14.0% for cisplatin/gemcitabine, respectively. PFS was also noninferior (cisplatin/pemetrexed median PFS, 4.8 months; cisplatin/gemcitabine median PFS, 5.1 months; HR ϭ 1.04; 95% CI, 0.94 to 1.15; Fig 2) , as was time to progressive disease. Objective response rates were comparable for the two arms (cisplatin/pemetrexed ϭ 30.6%; cisplatin/gemcitabine ϭ 28.2%), whereas duration of response was longer for cisplatin/gemcitabine than cisplatin/pemetrexed (4.5 v 5.1 months), although neither comparison was statistically significant.
In a Cox adjusted analysis (similar to the primary analysis of survival) to which smoking status was added, current/former smokers had a significantly higher risk of death compared with never-smokers (HR ϭ 1.74, test for superiority P Ͻ .001), even after controlling for treatment and the other four covariates. This effect of smoking status was also demonstrated in unadjusted analyses, in which the median survival time for never-smokers was 15.9 months compared with 10.0 months for former/current smokers on the cisplatin/pemetrexed arm and the median survival time for never-smokers was 15.3 months compared with 10.3 months for former/current smokers on the cisplatin/gemcitabine arm. Figure 3 shows a plot of Cox adjusted survival HRs (with 95% CIs) for the preplanned analyses that evaluated differences in overall survival with respect to baseline characteristics. The effect on survival of cisplatin/pemetrexed relative to cisplatin/gemcitabine was significantly different according to nonsquamous (large-cell carcinoma plus adenocarcinoma) versus squamous histology. The treatment-byhistology interaction analysis (P ϭ .0011) also showed that overall survival for patients with nonsquamous histology was significantly improved on the cisplatin/pemetrexed arm compared with the overall survival for all other patients with nonsquamous or squamous histology, thus confirming the analysis shown in Figure 3 .
The analyses of overall survival by treatment arm for each of three histologic groups (large-cell carcinoma, adenocarcinoma, and squamous) demonstrated that cisplatin/pemetrexed in patients with adenocarcinoma and large-cell carcinoma resulted in significantly better survival than cisplatin/gemcitabine (adenocarcinoma: n ϭ 847, 12.6 v 10.9 months, respectively; HR ϭ 0.84; 95% CI, 0.71 to 0.99; P ϭ .03; large-cell carcinoma: n ϭ 153, 10.4 v 6.7 months, respectively; HR ϭ 0.67; 95% CI, 0.48 to 0.96; P ϭ .03; nonsquamous: n ϭ 1,000, 11.8 v 10.4 months, respectively; HR ϭ 0.81; 95% CI, 0.70 to 0.94; P ϭ .005). Patients with squamous histology assigned to cisplatin/ pemetrexed (n ϭ 244) had a median survival time of 9.4 months, whereas patients assigned to cisplatin/gemcitabine (n ϭ 229) had a median survival time of 10.8 months (HR ϭ 1.23; 95% CI, 1.00 to 1.51; P ϭ .05). Figure 2 shows the Kaplan-Meier overall survival by treatment arm for the nonsquamous and the squamous histologic groups. The overall survival for a fourth group, consisting of all those patients in whom a generic cytologic diagnosis of NSCLC without further subtype classification was made (n ϭ 252), did not show a significant difference between the two arms; in this group, patients assigned to cisplatin/pemetrexed had a median survival time of 8.6 months compared with 9.2 months for patients assigned to cisplatin/ gemcitabine (HR ϭ 1.08; 95% CI, 0.81 to 1.45; P ϭ .586). When analyzed according to other baseline and disease characteristics, survival was consistent with the overall study results ( Table 3 ). Factors that had a statistically significant (P Ͻ .05) prognostic impact on survival (independent of treatment) included sex, race, performance status, disease stage, and histology. ‫ء‬ One patient on the cisplatin/pemetrexed arm received more than six cycles. †Four patients on the cisplatin/gemcitabine arm received more than six cycles.
Safety
Key hematologic grade 3 or 4 drug-related toxicities were significantly (P Յ .001) lower for cisplatin/pemetrexed compared with cisplatin/gemcitabine (neutropenia, 15% v 27%; anemia, 6% v 10%, and thrombocytopenia, 4% v 13%, respectively). For cisplatin/pemetrexed versus cisplatin/gemcitabine, drug-related grade 3 or 4 febrile neutropenia (1% v 4%, respectively; P ϭ .002) and alopecia (all grades; 12% v 21%, respectively; P Ͻ .001) were also significantly lower, whereas drug-related grade 3 or 4 nausea (7% v 4%, respectively; P ϭ .004) was higher (Table 4) . Safety within the histology groups was generally consistent with the overall safety results.
There were no statistically significant differences in hospital admissions or hospital days per patient observed between the study arms. Patients on the cisplatin/pemetrexed arm versus the cisplatin/ gemcitabine arm received significantly fewer transfusions (16.4% v 28.9%, respectively; P Ͻ .001), including RBC transfusions (16.1% v 27.3%, respectively; P Ͻ .001) and platelet transfusions (1.8% v 4.5%, respectively; P ϭ .002); the administration of erythropoietic (10.4% v 18.1%, respectively; P Ͻ .001) and granulocyte colony-stimulating factors (3.1% v 6.1%, respectively; P ϭ .004) was significantly lower in favor of cisplatin/pemetrexed.
There was no significant difference (P ϭ .387) between treatment arms in the incidence of or reason for the 116 deaths (7%) that occurred during study treatment. Each investigator categorized the deaths as caused by study disease, possibly caused by study drug, or as a result of other causes. Deaths attributed to study drug toxicity were low and were similar between arms (nine patients [1.0%] for cisplatin/pemetrexed, and six patients [0.7%] for cisplatin/gemcitabine).
Postdiscontinuation Therapies
Data regarding additional lines of therapy were prospectively collected; decisions regarding which therapies to use were made by the Survival Time (months) in All Patients individual investigators. Overall, 56.1% of cisplatin/gemcitabine patients and 52.6% of cisplatin/pemetrexed patients received an additional line of therapy. The types of agents administered were well balanced on the two arms, with the exception of more frequent pemetrexed use on the cisplatin/gemcitabine arm (13.4% v 3.5% on the cisplatin/pemetrexed arm; P Ͻ .001) and more frequent gemcitabine use on the cisplatin/pemetrexed arm (16.7% v 8.6% on the cisplatin/ gemcitabine arm; P Ͻ .001). Docetaxel was administered in 27.6% and 25.4% of patients and epidermal growth factor receptor tyrosine kinase inhibitors were administered in 22.5% and 24.9% of patients on the cisplatin/gemcitabine and cisplatin/pemetrexed arms, respectively. The distribution of postdiscontinuation therapies in each histologic group was similar to that of the overall study group.
DISCUSSION
In this randomized study, to our knowledge the largest ever conducted in the first-line setting of advanced NSCLC, cisplatin/pemetrexed was noninferior to cisplatin/gemcitabine. Survival, as well as other efficacy outcomes (PFS, 1-and 2-year survival rates, and response rates), for cisplatin/pemetrexed compares favorably with recent, first-line, NSCLC randomized clinical trials evaluating other platinum doublets (median survival time ranging from 7.4 to 10.1 months). [2] [3] [4] [5] The modest improvement in survival observed on both arms of this study compared with previous studies of platinum-based regimens 2-4 may have been influenced by several factors including improvements in NSCLC clinical staging, a relatively higher proportion of stage IIIB patients, or the exclusion of patients with a performance status of 2. In addition, enrollment onto this study reflects the relative increase in the proportion of adenocarcinoma, 28 a favorable prognostic factor observed in the overall NSCLC population, which was confirmed in this study. The combination of cisplatin/pemetrexed demonstrated a better safety profile compared with cisplatin/gemcitabine as documented by fewer dose adjustments, lower incidences of drug-related grade 3 or 4 hematologic toxicities, and a significantly lower incidence of febrile neutropenia, even though patients on both arms received a similar number of treatment cycles. In addition, patients treated with cisplatin/gemcitabine required significantly more transfusions and supportive care interventions (ie, hematopoietic growth factor support) than did patients on the cisplatin/pemetrexed arm.
An intriguing aspect of this study occurred in the prespecified analyses for survival with respect to histology, in which a significant survival difference in favor of cisplatin/pemetrexed occurred in two histologic groups (adenocarcinoma, n ϭ 847; and large-cell carcinoma, n ϭ 153). For patients with adenocarcinoma randomly assigned to cisplatin/pemetrexed, survival was significantly better than for those assigned to cisplatin/gemcitabine (12.6 v 10.9 months, respectively; P ϭ .03). One potential explanation may relate to thymidylate synthase expression levels in NSCLC histologic types. Preclinical data have indicated that overexpression of thymidylate synthase correlates with reduced sensitivity to pemetrexed. 29, 30 A recent study in chemotherapy-naive patients with adenocarcinoma or squamous cell carcinoma of the lung demonstrated that the baseline expression of the thymidylate synthase gene and protein were significantly higher in squamous cell carcinoma compared with adenocarcinoma (P Ͻ .0001). 31 In addition, thymidylate synthase and S phase kinase-associated protein (Skp2) are transcriptionally regulated in the S phase of the cell cycle by the transcription factor E2F-1. 32, 33 Like thymidylate synthase, elevated expression of Skp2 has been more commonly found in patients with squamous cell carcinoma of the lung than in patients with adenocarcinoma. 34 In a large, randomized, phase II trial of 441 patients that compared docetaxel/gemcitabine with docetaxel/cisplatin, no statistical difference in the efficacy outcomes was seen, but histology was the main predictive factor for response rate in each treatment group. 35 In our study, significantly improved overall survival for cisplatin/pemetrexed compared with cisplatin/gemcitabine was also observed in patients with large-cell carcinoma histology (10.4 v 6.7 months, respectively; P ϭ .03). To our knowledge, levels of thymidylate synthase expression in large-cell carcinoma of the lung have not been previously described. Despite the uncommon prevalence of this histologic type, further investigation of this association is warranted.
Although direct comparisons of efficacy across different randomized clinical studies may lead to biased conclusions as a result of differing patient populations, clinicians may consider cisplatin/pemetrexed to be an attractive alternative to bevacizumab-containing regimens (with either paclitaxel/carboplatin 16 or gemcitabine/cisplatin 17 ) for patients with nonsquamous tumors. The evaluation of treatment options for these patients must consider both the efficacy of these regimens and the different safety profiles of these combinations. 
